Journal of Clinical & Experimental OncologyISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Joanna Skubis-ZegadÅ?o Author

jzegadlo@wum.edu.pl 48 22 57 20 977

Subjects of specialization
Mucoepidermoid carcinoma, Cancer chemotherapy, Prostate biomarker, Endometrial cancer

Affiliation
Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland

Biography

Joanna Skubis-ZegadÅ‚o was working in the Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland. He has more than 40 publications. His current research area related to osteoarthropathy. 

Publications

Research Article Subscription

Anti Adeno-Associated Virus 2 (AAV) Antibody Profile in Ovarian Cancer Ascitic Fluid: Implications for AAV Intraperitoneal Gene Therapy

Author(s):

Joanna Skubis-Zegadło, Magdalena Kowalska, Beata Spiewankiewicz, Wacław Smiert Krzysztof Gawrychowski and Maciej Małecki

Objective: Recombinant adeno-associated virus (rAAV) type 2 is a common vector used in gene therapy. However, the presence of anti-AAV2 neutralizing antibodies or other neutralizing factors can significantly limit effective transduction. Intraperitoneal gene therapy could enable local delivery of the target gene directly to ovarian cancer cells. Until now, there have been no reports on the presence of anti-AAV antibodies in ascitic fluid, which might limit the effectiveness of rAAV as a candidate vector for intraperitoneal gene therapy. Thus, the characterization of the preexisting neutralization antibodies in ascitic fluid will provide insight into successful intraperitoneal gene therapy.

Methods... view more»

DOI: 10.4172/2324-9110.1000183

Abstract HTML PDF Supplementary File

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP